Daphnetin: a novel antimalarial agent with in vitro and in vivo activity.
Daphnetin is a dihydroxycoumarin that is being used in China for the treatment of coagulation disorders. It is also a chelator and an antioxidant. In vitro, daphnetin causes a 50% inhibition (IC50) of 3H-hypoxanthine incorporation by Plasmodium falciparum at concentrations between 25 and 40 microM. Several related compounds, such as scopoletin, 2, 3-dihydroxybenzoic acid and 3, 4-dihydroxybenzoic acid show no inhibitory activity. The antimalarial activity of daphnetin is inhibited by the addition of iron. Daphnetin does not appear to be an oxidant drug, since it does not spontaneously generate superoxide in vitro. However, it does alkylate bovine serum albumin when incubated in the presence of iron. In vivo, daphnetin significantly prolongs survival of P. yoelli-infected mice.
Yang
Y Z
YZ
Department of Microbiology, City University of New York Medical School, New York.
Ranz
A
A
Pan
H Z
HZ
Zhang
Z N
ZN
Lin
X B
XB
Meshnick
S R
SR
D000818:Animals; D000962:Antimalarials / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D007501:Iron / Q000494:pharmacology; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D051379:Mice; D010963:Plasmodium falciparum / Q000187:drug effects*; D010967:Plasmodium yoelii / Q000187:drug effects*; D013481:Superoxides / Q000378:metabolism; D014468:Umbelliferones / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D000962:Antimalarials; D014468:Umbelliferones; D013481:Superoxides; D007501:Iron; C039952:daphnetin